SG10202006318TA - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition - Google Patents

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition

Info

Publication number: SG10202006318TA
Authority: SG; Singapore
Prior art keywords: adm; antibody; acute; adrenomedullin; scaffold
Prior art date: 2011-11-16

Application number

SG10202006318TA

Inventor

Andreas Bergmann

Original Assignee

Adrenomed Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-16

Filing date

2012-11-16

Publication date

2020-08-28

2012-11-16 Application filed by Adrenomed Ag filed Critical Adrenomed Ag

2020-08-28 Publication of SG10202006318TA publication Critical patent/SG10202006318TA/en

Links

208000030090 Acute Disease Diseases 0.000 title 1
208000017667 Chronic Disease Diseases 0.000 title 1
102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
206010053159 Organ failure Diseases 0.000 title 1
230000001154 acute effect Effects 0.000 title 1
230000001684 chronic effect Effects 0.000 title 1
230000004768 organ dysfunction Effects 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

SG10202006318TA 2011-11-16 2012-11-16 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition SG10202006318TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11189447		2011-11-16
EP12160014		2012-03-16

Publications (1)

Publication Number	Publication Date
SG10202006318TA true SG10202006318TA (en)	2020-08-28

Family

ID=48429015

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201801919QA SG10201801919QA (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SG11201402366PA SG11201402366PA (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SG10202006318TA SG10202006318TA (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG10201801919QA SG10201801919QA (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SG11201402366PA SG11201402366PA (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition

Country Status (18)

Country	Link
US (4)	US20140328853A1 (en)
EP (3)	EP3553084B1 (en)
JP (2)	JP6193871B2 (en)
AU (1)	AU2012338731B2 (en)
DK (2)	DK2780369T3 (en)
ES (2)	ES2938653T3 (en)
FI (1)	FI3553084T3 (en)
HR (2)	HRP20230146T1 (en)
HU (2)	HUE044383T2 (en)
LT (2)	LT3553084T (en)
NZ (1)	NZ624873A (en)
PL (2)	PL2780369T3 (en)
PT (2)	PT3553084T (en)
RS (2)	RS58880B1 (en)
SG (3)	SG10201801919QA (en)
SI (1)	SI3553084T1 (en)
WO (1)	WO2013072511A1 (en)
ZA (1)	ZA201906427B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015092021A1 (en) *	2013-12-20	2015-06-25	Spingotec Therapeutics Gmbh	Adrenomedullin binder for use in therapy of cancer
EP3339324A1 (en)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
WO2018109228A1 (en) *	2016-12-16	2018-06-21	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
CN111480076A (en)	2017-10-18	2020-07-31	艾德里诺医药公司	Therapy monitoring under treatment with anti-Adrenomedullin (ADM) binding agents
EP3871689A1 (en)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3172349A1 (en)	2020-02-27	2021-09-02	4TEEN4 Pharmaceuticals GmbH	Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
EP4110811A1 (en)	2020-02-27	2023-01-04	AdrenoMed AG	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CN115244081A (en)	2020-02-27	2022-10-25	艾德里诺医药公司	anti-Adrenomedullin (ADM) binding agents for the treatment of patients with shock
BR112022017890A2 (en)	2020-03-16	2022-11-01	Sphingotec Gmbh	PROADRENOMEDULLIN OR FRAGMENT OF THE SAME IN PATIENTS INFECTED WITH CORONAVIRUS AND TREATMENTS WITH LIGAND AGAINST ADRENOMEDULIN
CN111627559B (en) *	2020-06-17	2023-08-29	北京大学第三医院（北京大学第三临床医学院）	System for predicting patient mortality risk
WO2023175035A1 (en)	2022-03-15	2023-09-21	Adrenomed Ag	Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
WO2024023368A1 (en)	2022-07-29	2024-02-01	4TEEN4 Pharmaceuticals GmbH	Prediction of an increase of dpp3 in a patient with septic shock
WO2024023369A1 (en)	2022-07-29	2024-02-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en)	1988-08-01	1993-03-04	Ciba Corning Diagnostics Corp.	Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
SG48759A1 (en)	1990-01-12	2002-07-23	Abgenix Inc	Generation of xenogenic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE185601T1 (en)	1990-07-10	1999-10-15	Cambridge Antibody Tech	METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (en)	1993-04-26	1998-07-09	賢治寒川	Adrenomedullin
JPH11512087A (en)	1995-08-18	1999-10-19	アメリカ合衆国	Functional role of adrenomedullin (AM) and gene-related product (PAMP) in human pathology and physiology
CA2242308A1 (en)	1997-12-08	1999-06-08	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
DE19847690A1 (en)	1998-10-15	2000-04-20	Brahms Diagnostica Gmbh	Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
PT1214600E (en) *	1999-09-10	2006-05-31	Us Gov Health & Human Serv	DETERMINATION OF PROTEINS FROM LIGACAO TO ADRENOMEDULIN
CA2414073A1 (en)	2001-05-04	2002-11-14	Gunars E. Valkirs	Diagnostic markers of acute coronary syndromes and methods of use thereof
EP1427750B1 (en)	2001-08-30	2010-12-08	Biorexis Pharmaceutical Corporation	Modified transferrin fusion proteins
US6864237B2 (en)	2002-05-17	2005-03-08	Ping Wang	Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
WO2003103475A2 (en)	2002-06-07	2003-12-18	Dyax Corp.	Prevention and reduction of blood loss
DE10316583A1 (en)	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination
EP1620734A1 (en)	2003-04-25	2006-02-01	Genova Ltd.	Secreted polypeptide species reduced cardiovascular disorders
US6884781B2 (en)	2003-05-16	2005-04-26	Ping Wang	Treatment of shock using adrenomedullin binding protein-1
US20050164301A1 (en)	2003-10-24	2005-07-28	Avidia Research Institute	LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en)	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
EP1800131A2 (en)	2004-09-09	2007-06-27	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2006032436A2 (en)	2004-09-21	2006-03-30	Nascacell Technologies Ag.	Use of microproteins as tryptase inhibitors
US9829494B2 (en)	2005-12-01	2017-11-28	Adrenomed Ag	Methods of treatment using ADM antibodies
US7825217B2 (en)	2006-09-15	2010-11-02	University Of Kansas Medical Center	Polypeptides for bone mineralization
KR101686247B1 (en) *	2007-10-31	2016-12-14	메디뮨 엘엘씨	Protein scaffolds
ES2373832T3 (en)	2007-12-19	2012-02-09	Affibody Ab	POLYPEPTIDE DERIVED FROM PROTEIN A AND ABLE TO JOIN PDGF.
DK2358746T3 (en)	2008-11-03	2020-12-21	Molecular Partners Ag	BINDING PROTEINS TO INHIBIT THE VEGF-A RECEPTOR INTERACTION
AU2010288542B2 (en)	2009-08-27	2014-05-22	Covagen Ag	IL-17 binding compounds and medical uses thereof
KR101353677B1 (en)	2009-12-14	2014-02-12	쉴 프로테인즈 게엠베하	Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
DE102010040035A1 (en)	2010-03-04	2011-09-08	Robert Bosch Gmbh	Improvements to backward analysis to determine error masking factors
WO2011154420A2 (en)	2010-06-08	2011-12-15	Pieris Ag	Tear lipocalin muteins binding il-4 r alpha
FR2964103B1 (en)	2010-08-30	2018-11-23	Universite D'aix-Marseille	ANTIBODIES BINDING TO ADRENOMEDULLINE AND RECEPTORS OF ADRENOMEDULLINE AND THEIR USES AS A MEDICINAL PRODUCT
PL2780717T3 (en)	2011-11-16	2017-06-30	Sphingotec Gmbh	Adrenomedullin assays and methods for determining mature adrenomedullin

2012
- 2012-11-16 RS RS20190738A patent/RS58880B1/en unknown
- 2012-11-16 HR HRP20230146TT patent/HRP20230146T1/en unknown
- 2012-11-16 ES ES19162009T patent/ES2938653T3/en active Active
- 2012-11-16 EP EP19162009.5A patent/EP3553084B1/en active Active
- 2012-11-16 AU AU2012338731A patent/AU2012338731B2/en active Active
- 2012-11-16 LT LTEP19162009.5T patent/LT3553084T/en unknown
- 2012-11-16 PL PL12784631T patent/PL2780369T3/en unknown
- 2012-11-16 JP JP2014541695A patent/JP6193871B2/en active Active
- 2012-11-16 PT PT191620095T patent/PT3553084T/en unknown
- 2012-11-16 PT PT12784631T patent/PT2780369T/en unknown
- 2012-11-16 DK DK12784631.9T patent/DK2780369T3/en active
- 2012-11-16 WO PCT/EP2012/072930 patent/WO2013072511A1/en active Application Filing
- 2012-11-16 DK DK19162009.5T patent/DK3553084T3/en active
- 2012-11-16 FI FIEP19162009.5T patent/FI3553084T3/en active
- 2012-11-16 EP EP21216077.4A patent/EP4086283A1/en active Pending
- 2012-11-16 SG SG10201801919QA patent/SG10201801919QA/en unknown
- 2012-11-16 HU HUE12784631 patent/HUE044383T2/en unknown
- 2012-11-16 SG SG11201402366PA patent/SG11201402366PA/en unknown
- 2012-11-16 RS RS20230115A patent/RS64060B1/en unknown
- 2012-11-16 PL PL19162009.5T patent/PL3553084T3/en unknown
- 2012-11-16 LT LTEP12784631.9T patent/LT2780369T/en unknown
- 2012-11-16 EP EP12784631.9A patent/EP2780369B1/en active Active
- 2012-11-16 NZ NZ624873A patent/NZ624873A/en unknown
- 2012-11-16 US US14/358,334 patent/US20140328853A1/en not_active Abandoned
- 2012-11-16 SG SG10202006318TA patent/SG10202006318TA/en unknown
- 2012-11-16 HU HUE19162009A patent/HUE061696T2/en unknown
- 2012-11-16 ES ES12784631T patent/ES2729710T3/en active Active
- 2012-11-16 SI SI201232021T patent/SI3553084T1/en unknown
2016
- 2016-02-16 US US15/044,474 patent/US10221238B2/en active Active
2017
- 2017-05-17 JP JP2017098527A patent/JP2017155051A/en active Pending
2018
- 2018-09-20 US US16/136,892 patent/US10800842B2/en active Active
- 2018-12-10 US US16/214,963 patent/US11673949B2/en active Active
2019
- 2019-06-04 HR HRP20191010TT patent/HRP20191010T1/en unknown
- 2019-09-30 ZA ZA2019/06427A patent/ZA201906427B/en unknown

Also Published As

Publication number	Publication date
HUE061696T2 (en)	2023-08-28
RS58880B1 (en)	2019-08-30
LT2780369T (en)	2019-07-10
EP3553084B1 (en)	2022-11-16
US20190092857A1 (en)	2019-03-28
EP4086283A1 (en)	2022-11-09
US10800842B2 (en)	2020-10-13
HRP20191010T1 (en)	2019-08-23
EP2780369A1 (en)	2014-09-24
US10221238B2 (en)	2019-03-05
SG10201801919QA (en)	2018-04-27
EP2780369B1 (en)	2019-03-13
US20140328853A1 (en)	2014-11-06
DK3553084T3 (en)	2023-02-20
HUE044383T2 (en)	2019-10-28
PT3553084T (en)	2023-02-17
ZA201906427B (en)	2020-08-26
AU2012338731B2 (en)	2017-07-06
ES2729710T3 (en)	2019-11-05
EP3553084A1 (en)	2019-10-16
US20190010226A1 (en)	2019-01-10
JP6193871B2 (en)	2017-09-06
WO2013072511A1 (en)	2013-05-23
PL2780369T3 (en)	2019-09-30
NZ624873A (en)	2016-07-29
DK2780369T3 (en)	2019-06-17
SG11201402366PA (en)	2014-06-27
AU2012338731A1 (en)	2014-05-29
PL3553084T3 (en)	2023-04-17
JP2015501797A (en)	2015-01-19
US11673949B2 (en)	2023-06-13
JP2017155051A (en)	2017-09-07
HRP20230146T1 (en)	2023-04-28
SI3553084T1 (en)	2023-05-31
FI3553084T3 (en)	2023-03-03
PT2780369T (en)	2019-06-18
RS64060B1 (en)	2023-04-28
ES2938653T3 (en)	2023-04-13
LT3553084T (en)	2023-03-10
US20160176960A1 (en)	2016-06-23

Publication	Publication Date	Title
ZA201906427B (en)	2020-08-26	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SG11201402362VA (en)	2014-06-27	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
HRP20190122T1 (en)	2019-03-08	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
MY174877A (en)	2020-05-20	Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition
HK1202127A1 (en)	2015-09-18	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy (adm) adm adm ig
ZA201403549B (en)	2022-11-30	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EP2164505A4 (en)	2010-12-22	Treatment of chronic lung disease
IL216804A0 (en)	2012-02-29	Methods for treating chronic kidney disease
HK1159104A1 (en)	2012-07-27	Therapeutic agent for chronic renal failure
HK1198947A1 (en)	2015-06-19	Thromboembolism preventive therapeutic agent for thromboembolism patients having severe renal dysfunction
GB0816025D0 (en)	2008-10-08	Medicament for the treatment of chronic obstructive pulmonary disease (COPD)
TH107841B (en)	2011-05-12	Pharmaceutical components for the prevention or treatment of chronic obstructive pulmonary disease.